臨床外科68巻6号

2013年06月発行

特集 胃癌腹膜転移治療の最前線

胃癌腹膜転移に対する標準治療とは

著者： 津田享志¹ 中島貴子¹

所属機関： ¹聖マリアンナ医科大学臨床腫瘍学

ページ範囲：P.642 - P.646

【ポイント】

◆胃癌腹膜転移例は腹水貯留，腸閉塞，尿管閉塞による水腎症，総胆管閉塞など様々な病態を呈する．

◆軽度から中等度の腹膜転移症例は切除不能進行・再発胃癌の一般的な標準治療（SP療法）を行えることが多い．

◆高度の腹膜転移症例に対しての化学療法は，SP療法などの標準治療ではなく，別途開発が必要である．

参考文献

1）Maehara Y, Hasuda S, Koga T, et al：Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87：353-357, 2000

2）Cunningham D, Starling N, Rao S, et al：Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358：36-46, 2008

3）Van Cutsem E, Moiseyenko VM, Tjulandin S, et al：Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer：a report of the V325 Study Group. J Clin Oncol 24：4991-4997, 2006

4）Boku N, Yamamoto S, Fukuda H, et al：Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer：a randomised phase 3 study. Lancet Oncol 10：1063-1069, 2009

5）Koizumi W, Narahara H, Hara T, et al：S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer（SPIRITS trial）：a phase Ⅲ trial. Lancet Oncol 9：215-221, 2008

6）Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomised controlled trial. Lancet 376：687-697, 2010

7）Sakuramoto S, Sasako M, Yamaguchi T, et al：Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357：1810-1820, 2007

8）Nakagawa S, Nnashimoto A, Yabusaki H：Neoadjuvant chemotherapy for patients with positive cytology from advanced gastric cancer. Jpn J Cancer Chemother 33：1774-1776, 2006

9）Shirao K, Boku N, Yamada K, et al：Randomized phaseⅢ study of 5-fluorouracil continuous infusion（5-FUci）versus methotrexate and 5-FU sequential therapy（MF）in gastric cancer with peritoneal metastasis：JCOG 0106. American Society of Clinical Oncology：#4545, 2009

10）Kim WH, Koizumi W, Lee KH, et al：Randomized phaseⅢ study of S-1 alone versus S-1 plus docetaxel in the treatment for advanced gastric cancer. The START trial. ASCO GI symposium San Francisco, CA：#7, 2011

11）Sawaki A, Yamaguchi K, Nabeya Y, et al：5-FU/l-LV（RPMI）vesus S-1 as first-line therapy in patients with advanced gastric cancer. a randmized phaseⅢ non-inferiority trial. （ISO-5FU10 Study Group trial）. European Society of Medical Oncology：#509, 2009

12）Takiuchi H, Yasui H, Nishina T, et al：Multicenter feasibility study of 5-FU, leucovorin, plus paclitaxel（FLTAX）for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake. American Society of Clinical Oncology, Gastrointestinal Cancer Symposium：#119, 2011

13）De Vita F, Orditura M, Matano E, et al：A phaseⅡ study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid（FOLFOX-4）as first-line treatment of advanced gastric cancer patients. Br J Cancer 92：1644-1649, 2005

14）Louvet C, Andre T, Tigaud JM, et al：PhaseⅡ study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20：4543-4548, 2002

15）Oh SY, Kwon HC, Seo BG, et al：A phaseⅡ study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil（modified FOLFOX-4）as first line therapy for patients with advanced gastric cancer. Acta Oncol 46：336-341, 2007

16）Oh SY, Kwon HC, Lee S, et al：A PhaseⅡ study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil（modified FOLFOX-4）for gastric cancer patients with malignant ascites. Jpn J Clin Oncol 37：930-935, 2007

17）Thuss-Patience PC, Kretzschmar A, Bichev D, et al：Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer―a randomised phaseⅢ study of the Arbeitsgemeinschaft Internistische Onkologie（AIO）. Eur J Cancer 47：2306-2314, 2011

18）Kang JH, Lee SI, Lim do H, et al：Salvage chemotherapy for pretreated gastric cancer：a randomized phaseⅢ trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30：1513-1518, 2012

19）Arai T, Hamaguchi T, Shirao K, et al：Weekly paclitaxel in patients with heavily treated advanced gastric cancer. American Society of Clinical Oncology：#1291, 2003

20）Hironaka S, Zenda S, Boku N, et al：Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9：14-18, 2006

21）Ueda S, Hironaka S, Yasui H, et al：Randomized phaseⅢ study of irinotecan（CPT-11）versus weekly paclitaxel（wPTX）for advanced gastric cancer（AGC）refractory to combination chemotherapy（CT）of fluoropyrimidine plus platinum（FP）：WJOG4007 trial. American Society of Clinical Oncology：#4002, 2012

22）Takiuchi H, Fukuda H, Boku N, et al：Randmized phaseⅡ study of best-available 5-fluorouracil（5-FU）versus weekly paclitaxel in gastric cancer with peritoneal metastasis（PM）refractory to 5-FU containing regimens：JCOG0407. American Society of Clinical Oncology：#4052, 2010